BTIG Affirms Ophthotech (OPHT) at 'Buy' Amid Recent Regeneron Data; Says Focus Should be on Fovista

October 3, 2016 12:31 PM EDT
Get Alerts OPHT Hot Sheet
Price: $4.61 -0.22%

Rating Summary:
    4 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade OPHT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

BTIG affirms Ophthotech (Nasdaq: OPHT) at Buy with a price target of $92 following recent data for Regeneron’s co-formulary compound REGN2176-3.

Analyst Ling Wang noted the following on Sunday:

  • REGN2176-3 efficacy underperforms Fovista in both Phase I and Phase II. Development of a drug candidate should build on prior studies. Therefore, it should not be a huge surprise that REGN2176-3 failed in Phase II, given the lackluster Phase I efficacy.
  • Meaningful differences could make or fail a drug. Fovista inhibits PDGF signaling at the ligand level, which theoretically could have advantages over targeting PDGFR-ß of REGN2176-3 (supported by literature), given the broader downstream ligand/receptor interactions impacted. Additionally, Fovista, an aptamer, may offer a better Adverse Events (AE) profile than antibody fragment. Potential protein-protein interaction in a small volume (50uL single injection) may negatively impact the efficacy of REGN2176-3 (with a less mean improvement in VA than Eylea alone).
  • Competitor setback a long term positive. With one less competitor, one could argue higher Fovista peak sales assuming successful Phase III trial (we choose not to factor in our model currently), which suggests higher upside upon Phase III success.

For an analyst ratings summary and ratings history on Ophthotech Corp click here. For more ratings news on Ophthotech Corp click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities


Add Your Comment